Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04923672
Other study ID # 210103
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date February 20, 2023
Est. completion date August 1, 2025

Study information

Verified date August 2023
Source University of Virginia
Contact Ryan Gombita
Phone (434) 924-5529
Email KRA9HY@uvahealth.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Studies have shown that people who are more physically fit prior to surgery do better after surgery. For this reason, it may be helpful for people who are going to have abdominal surgery for cancer to exercise before surgery to increase fitness. In this study, patients will be assigned to either maintain their current activity, or increase activity to 5 days a week, 40 minutes per day, of either continuous moderate activity or intervals of moderate and vigorous activity (three groups). All participants will wear an Apple watch, and participants in the exercise groups will use a smartphone application to get feedback on activity and encouragement to reach activity goals.


Description:

Research indicates that people who have better physical fitness at the time of surgery have a better chance of surviving the surgery and returning to normal function. An exercise intervention in the 3+ weeks before surgery (after the decision that surgery is necessary) may help people who are going to have abdominal surgery for cancer increase fitness prior to surgery. Devices that track physical activity, like smartwatches or Fitbits, allow the wearer to get feedback on physical activity information like steps taken, distance traveled, time in light, moderate or vigorous activity and on heart rate. Having this information and using a smartphone application designed to increase physical activity may help patients increase physical activity and thereby fitness, prior to abdominal surgery for cancer. The main goal of this project is to test two physical activity interventions and also a "control group" to make sure that participants can do the interventions and to see whether there are changes in activity and fitness in each group: 1. Control group - maintain current activity 2. Moderate continuous activity group - increase activity to 5 days a week, 40 minutes per day, of continuous moderate activity 3. High Intensity Interval Training group - increase activity to 5 days a week, 40 minutes per day, of intervals of moderate and vigorous activity All participants will wear an Apple watch, and participants in the exercise groups will use a smartphone application to get feedback on activity and encouragement to reach activity goals. Optional: Participants will also be asked to provide a small amount of blood for research purposes.


Recruitment information / eligibility

Status Recruiting
Enrollment 57
Est. completion date August 1, 2025
Est. primary completion date August 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Adult (= 18 years of age) patients undergoing elective abdominal oncologic resection of a confirmed or potential colorectal, hepatobiliary, or gynecologic neoplasm. - Study participants must be able to provide written informed consent and authorization. - Study participants must be able to understand written and verbal English, as well as to be able to communicate in English. - Study participants must have an Apple iphone to use during the study period Exclusion Criteria: - Any patient unable and/or unwilling to cooperate with all study protocols. - Patients who require an assist device (walker) for ambulation. - Patients that indicate they did at least 3 days of vigorous intensity activity in the previous 7 days OR any combination of walking, moderate-intensity or vigorous-intensity in all of the last 7 days totaling at least 18 and a half hours - Recent history of cardiac disease (within 3 months of registration) that would preclude vigorous exercise - Individuals with end stage renal disease currently on dialysis - Individuals with a history of liver failure as evidenced by AST, ALT or Alkaline Phosphatase = 3x upper limit of normal - Individuals with uncontrolled hypertension - Women who are breastfeeding or pregnant - American Society of Anesthesiologists Physical Status score = 4 - Any patient that needs further cardiac evaluation per ACC/AHA perioperative criteria - Surgery scheduled < 3 weeks of study registration (precluding time to participate in exercise regimen) - Any patient who currently uses a fitness tracker or heart rate monitoring-capable device to guide exercise - Patient indicates a lack of familiarity or discomfort with using a smartphone - If participation is not in the best interest of the patient, in the opinion of the treating investigator

Study Design


Intervention

Behavioral:
Moderate continuous exercise
Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of continuous moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.
High intensity interval exercise
Participants will be asked to wear an Apple watch and use a smartphone application to help increase their activity to 5 days a week, about 40 minutes a day of intervals of high and moderate intensity exercise prior to surgery. They will be asked to continue wearing the watch through about 30 days after surgery.

Locations

Country Name City State
United States UVA Health System Charlottesville Virginia

Sponsors (1)

Lead Sponsor Collaborator
University of Virginia

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Steps per day Change in average steps per day measured at baseline and at the time of surgery Baseline through the 1 day visit prior to surgery
Secondary Enrollment rate Number of participants enrolled per month During participant accrual, estimated to take about 12 months
Secondary Compliance with EXi smartphone application To assess feasibility of the intervention From baseline through 1 day visit just prior to surgery
Secondary Compliance with exercise intervention, including percentage of exercise goals reached To assess feasibility of the intervention From baseline through 1 day visit just prior to surgery
Secondary Completion/Dropout rate To assess feasibility of the intervention From baseline through about 30 days after surgery
Secondary Percentage of time wearing Apple Watch To assess feasibility of the intervention From baseline through about 30 days after surgery
Secondary Health-related quality of life As measured by PROMIS Global Health Scale Baseline and 1 day of surgery
Secondary Pain intensity As measured by PROMIS Pain intensity Baseline and 1 day of surgery
Secondary Pain interference As measured by PROMIS Pain interference Baseline and 1 day of surgery
Secondary Physical activity level by self report As measured by the International Physical Activity Questionnaire Baseline and 1 day of surgery
Secondary Surgical complications Based on review of medical records 30 days after surgery
Secondary Length of hospital stay (in days) following surgery Days participant stayed in hospital following surgery date Up to 30 days following surgery
Secondary Steps per day Measured by Apple Watch From baseline through 30 days after surgery
Secondary Fitness level As measured by 6 minute walk test Baseline, 1 day prior to surgery, and 30, 90, and 180 days following surgery
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Active, not recruiting NCT05551052 - CRC Detection Reliable Assessment With Blood
Completed NCT00098787 - Bevacizumab and Oxaliplatin Combined With Irinotecan or Leucovorin and Fluorouracil in Treating Patients With Metastatic or Recurrent Colorectal Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05425940 - Study of XL092 + Atezolizumab vs Regorafenib in Subjects With Metastatic Colorectal Cancer Phase 3
Suspended NCT04595604 - Long Term Effect of Trimodal Prehabilitation Compared to ERAS in Colorectal Cancer Surgery. N/A
Completed NCT03414125 - Effect of Mailed Invites of Choice of Colonoscopy or FIT vs. Mailed FIT Alone on Colorectal Cancer Screening N/A
Completed NCT02963831 - A Study to Investigate ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Phase 1/Phase 2
Recruiting NCT05489211 - Study of Dato-Dxd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03) Phase 2
Terminated NCT01847599 - Educational Intervention to Adherence of Patients Treated by Capecitabine +/- Lapatinib N/A
Completed NCT05799976 - Text Message-Based Nudges Prior to Primary Care Visits to Increase Care Gap Closure N/A
Recruiting NCT03874026 - Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients Phase 2
Active, not recruiting NCT03170960 - Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors Phase 1/Phase 2
Completed NCT03181334 - The C-SPAN Coalition: Colorectal Cancer Screening and Patient Navigation N/A
Completed NCT03167125 - Participatory Research to Advance Colon Cancer Prevention N/A
Recruiting NCT04258137 - Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study N/A
Not yet recruiting NCT05775146 - SBRT of Metastases Following Neo-adjuvant Treatment for Colorectal Cancer With Synchronous Liver Metastases Phase 2
Recruiting NCT05568420 - A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Recruiting NCT02972541 - Neoadjuvant Chemotherapy Verse Surgery Alone After Stent Placement for Obstructive Colonic Cancer N/A
Completed NCT02876224 - Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors Phase 1